Asset Details
Do you wish to reserve the book?
ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation
Do you wish to request the book?
ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation
2022
Overview
Estrogen receptor alpha (ER/
ESR1
) is frequently mutated in endocrine resistant ER-positive (ER+) breast cancer and linked to ligand-independent growth and metastasis. Despite the distinct clinical features of
ESR1
mutations, their role in intrinsic subtype switching remains largely unknown. Here we find that
ESR1
mutant cells and clinical samples show a significant enrichment of basal subtype markers, and six basal cytokeratins (BCKs) are the most enriched genes. Induction of BCKs is independent of ER binding and instead associated with chromatin reprogramming centered around a progesterone receptor-orchestrated insulated neighborhood. BCK-high ER+ primary breast tumors exhibit a number of enriched immune pathways, shared with
ESR1
mutant tumors. S100A8 and S100A9 are among the most induced immune mediators and involve in tumor-stroma paracrine crosstalk inferred by single-cell RNA-seq from metastatic tumors. Collectively, these observations demonstrate that
ESR1
mutant tumors gain basal features associated with increased immune activation, encouraging additional studies of immune therapeutic vulnerabilities.
Mutations of
ESR1
, the gene encoding the estrogen receptor alpha, are associated with acquired resistance to therapy in luminalbreast cancer. Here the authors show that
ESR1
mutant tumors gain basal-like features with increased expression of basal cytokeratines and immune activation.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 13/106
/ 13/51
/ 13/89
/ 38/39
/ 45/15
/ 49/88
/ 49/91
/ 59
/ Breast Neoplasms - pathology
/ Estrogen Receptor alpha - genetics
/ Estrogen Receptor alpha - metabolism
/ Female
/ Humanities and Social Sciences
/ Humans
/ Mutants
/ Mutation
/ Science
/ Stroma
/ Tumors
